LongBio Pharma Issues 2.13 Million New H Shares After Full Over-Allotment Exercise

Bulletin Express07-06

LongBio-B (LongBio Pharma (Suzhou) Co., Ltd.; HKEX: 01779) reported that on 6 July 2026 it issued and allotted 2.13 million new H shares following the full exercise of the over-allotment option disclosed on 30 June 2026. The new shares were priced at HKD 96.06 each, expanding the company’s issued H-share capital by 2.92%.

The transaction lifted LongBio Pharma’s outstanding H-share count from 72.93 million to 75.06 million. Based on the disclosed issue price, the share placement corresponds to gross proceeds of approximately HKD 204.51 million (about USD 26.19 million).

No treasury shares were created, sold, or cancelled in the period, leaving LongBio Pharma with zero treasury shares and a post-issuance total of 75.06 million issued shares as at 6 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130187592?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130187592","market":"us","top_or_hot":-1,"title":"LongBio Pharma Issues 2.13 Million New H Shares After Full Over-Allotment Exercise","media":"Bulletin Express","content":"<p>LongBio-B (LongBio Pharma (Suzhou) Co., Ltd.; HKEX: 01779) reported that on 6 July 2026 it issued and allotted 2.13 million new H shares following the full exercise of the over-allotment option disclosed on 30 June 2026. The new shares were priced at HKD 96.06 each, expanding the company’s issued H-share capital by 2.92%.</p>\n<p>The transaction lifted LongBio Pharma’s outstanding H-share count from 72.93 million to 75.06 million. Based on the disclosed issue price, the share placement corresponds to gross proceeds of approximately HKD 204.51 million (about USD 26.19 million).</p>\n<p>No treasury shares were created, sold, or cancelled in the period, leaving LongBio Pharma with zero treasury shares and a post-issuance total of 75.06 million issued shares as at 6 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LongBio Pharma Issues 2.13 Million New H Shares After Full Over-Allotment Exercise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongBio Pharma Issues 2.13 Million New H Shares After Full Over-Allotment Exercise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-06 19:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LongBio-B (LongBio Pharma (Suzhou) Co., Ltd.; HKEX: 01779) reported that on 6 July 2026 it issued and allotted 2.13 million new H shares following the full exercise of the over-allotment option disclosed on 30 June 2026. The new shares were priced at HKD 96.06 each, expanding the company’s issued H-share capital by 2.92%.</p>\n<p>The transaction lifted LongBio Pharma’s outstanding H-share count from 72.93 million to 75.06 million. Based on the disclosed issue price, the share placement corresponds to gross proceeds of approximately HKD 204.51 million (about USD 26.19 million).</p>\n<p>No treasury shares were created, sold, or cancelled in the period, leaving LongBio Pharma with zero treasury shares and a post-issuance total of 75.06 million issued shares as at 6 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01779","symbol_name":"天辰生物-B","start_time":0,"source_url":"","article_id":"1130187592","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130187592","pubTimestamp":1783337071,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"LongBio-B (LongBio Pharma (Suzhou) Co., Ltd.; HKEX: 01779) reported that on 6 July 2026 it issued and allotted 2.13 million new H shares following the full exercise of the over-allotment option...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01779":"天辰生物-B"},"translate_title":"龙生物制药于全数超额配股权行使后发行213万股新H股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01779":1},"content_text":"LongBio-B (LongBio Pharma (Suzhou) Co., Ltd.; HKEX: 01779) reported that on 6 July 2026 it issued and allotted 2.13 million new H shares following the full exercise of the over-allotment option disclosed on 30 June 2026. The new shares were priced at HKD 96.06 each, expanding the company’s issued H-share capital by 2.92%.\nThe transaction lifted LongBio Pharma’s outstanding H-share count from 72.93 million to 75.06 million. Based on the disclosed issue price, the share placement corresponds to gross proceeds of approximately HKD 204.51 million (about USD 26.19 million).\nNo treasury shares were created, sold, or cancelled in the period, leaving LongBio Pharma with zero treasury shares and a post-issuance total of 75.06 million issued shares as at 6 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130187592","isCrawlerRequest":true}